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Background of the study 
Age-related  macular  degeneration  (AMD)  is  the  leading  cause  of 
irreversible  vision  loss  among  people  over  65  years  in  the  USA  and 
Europe.  Symptomatically,  AMD varies  widely in severity ranging from 
slight distortions in mild cases to a complete loss of the central vision in 
the worst cases. So far treatment is limited and a promising strategy for a 
complete cure does not exist, mainly because the underlying cause is still 
unclear and remains a source of controversy.
Significant  similarities  between AMD and so  called  protein  misfolding 
disorders (PMDs) or amyloid diseases, such as Alzheimer disease (AD), 
diabetes type II  or Parkinson disease,  led to the assumption that  AMD 
could follow a similar pathogenic pathway that is believed to be common 
in all PMDs. Firstly, there is strong correlation with advancing age and 
secondly,  but  most  importantly  AMD  and  PMDs  are  unique  in  their 
pathological  feature  in  respect  to  the  abnormal  formation  and 
accumulation of deposits that compromise a mixture of numerous proteins. 
Since  these  deposits  can  be  observed  in  a  variety,  but  only  in  disease 
affected tissues, it is believed that characteristic PMD-associated protein 
deposits  are  in  a  cause-effect  relationship  or  at  least  contribute  to  the 
irreversible degenerative process that can be seen in the disease affected 
tissues. For instance, the extracellular formation of protein deposits in 
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cortical and cerebrovascular regions in AD- patients or the intracellular
formation of protein deposits in the pancreatic islets of diabetes type II-
patients are strongly associated with the development of each particular 
disease. Similar to AD and diabetes type II, AMD is characterized through 
extracellular  formations  of  protein  deposits  in  the  neural  retina  with 
increasing age and disease progress. In AMD these protein deposits are 
called drusen and their similarity with protein deposits of PMDs is striking 
in respect to their protein composition. Furthermore the close proximity of 
drusen  to  degenerated  photoreceptor-  and  retinal-pigmented  epithelium 
cells (RPE) indicates their significance in the pathogenesis of AMD in a 
similar way as it has been proposed for protein deposits in PMDs. 
Recent data from biochemical and pathological studies indicated that the 
underlying cause for PMDs could be the result  of an in vivo occurring 
protein misfolding process. In vitro studies demonstrated that this process 
could be described in a simplifying form as a multi-step cascade in which 
a specific disease-related protein (e.g. Aβ-peptide in AD, IAPP-peptide in 
diabetes  type  II)  undergoes  a  conformational  reorganization  from  a 
monomeric into an oligomeric structure that ultimately converts into an 
fibrillar structure. Eventually these fibrils are observed in form of 6- to 10 
nm filaments as the essential element within the PMD-associated protein 
deposits and therefore represent the common hallmark of all PMDs. For 
that reason amyloid fibrils have been so far the focus of research for many 
years  concerning  their  contribution  to  the  pathogenesis  of  PMDs. 
However, recent compelling pathological and biochemical data led to a 
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paradigm shift supporting the hypothesis that not the soluble monomers or 
insoluble fibrils but their oligomeric cascade predecessors are the primary 
underlying cause for tissue degeneration in PMDs. In vitro and in vivo 
studies demonstrated that amyloid oligomers, which are described as 3 to 
10 nm spherical  particles,  have the striking ability  to  permeabilize  cell 
membranes,  penetrate  into  cells,  disrupt  intracellular  membranes  and 
eventually lead to cell death. So far the toxic mechanism of oligomers is 
unknown  and  under  further  investigation,  but  recent  animal  models 
support the idea of oligomers as an underlying cause in the pathogenesis of 
PMDs, since their occurrence in disease-affected tissues correlates much 
better  with  emerging  clinical  symptoms and  degenerative  features  than 
with  amyloid  fibrils,  which  can  be  seen  mostly  post-symptomatically 
excluding their possibility to be a degenerative causing factor. 
Despite all similarities with PMDs, AMD has been so far not accepted as a 
“classical” PMD, mainly because drusen do not exhibit amyloid fibrils and 
amyloid fibrils are, as mentioned above, the common hallmark of PMDs 
and  are  the  only  accepted  indication  for  the  presence  of  a  protein 
misfolding process. However, recent in vitro studies demonstrated that a 
protein misfolding process  does not inevitable lead to  the formation of 
fibrils suggesting that pathogenic oligomers might be present within the 
disease-affected tissue even without accumulations of PMD characteristic 
amyloid  fibrils.  Recent  evidence  suggests  that  desmin-related 
cardiomyopathy  may  be  such  a  disease.  These  observations  raised  the 
questions if AMD might be such a “non-classical” PMD in which toxic 
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oligomers are present in the absence of  non-toxic fibrils.  Therefore the 
goal of this study was to investigate: (i) the presence and the morphology 
of oligomers in the neural retina of AMD affected and non-AMD affected 
eyes  (ii)  the  presence  of  oligomers  in  respect  to  drusen,  RPE  –  and 
photoreceptor cells that are the main affected cells in AMD and (iii) the 
toxic effect of a variety of oligomers towards RPE cells in vitro. 
For this purpose we took advantage of a recently developed conformation 
dependent “anti-oligomer” antibody that recognizes specifically oligomers 
of numerous disease-associated proteins, such as the aβ-peptide of AD, α-
synuclein  protein  of  PD  or  the  IAPP  peptide  of  diabetes  type  II. 
Furthermore this antibody inhibits the toxic effect of oligomers, suggesting 
that the “anti-oligomer” antibody indeed recognizes toxic oligomers.
Through  a  variety  of  methods,  such  as  confocal  immunofluorescence 
microscopy,  electron microscopy,  enzyme-linked immunosorbent  assays 
and  MTT  based  toxicity  assays  we  made  following  observations:  (i) 
oligomers are present in form of 100 nm small vesicles in the neural retina 
of  AMD  affected  donor-eyes,  but  not  in  AMD  unaffected  eyes  (ii) 
oligomers are located as well within drusen as in close proximity to RPE 
cells,  but  not to photoreceptor-cells (iii)  oligomers of numerous disease 
associated proteins are indeed toxic to RPE cells and their toxicity can be 
inhibited by the anti-oligomer antibody. 
In  summary  our  study  suggests  the  significance  of  oligomers  in  the 
pathogenesis of AMD and indicates that AMD shares commonalities with 
other PMDs in respect to protein missfolding.
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Introduction
The formation of insoluble extracellular deposits consisting of misfolded, 
aggregated  protein  is  a  hallmark  of  many  neurodegenerative diseases. 
Extracellular deposits are also present in aging human eyes and in eyes 
afflicted  by  age-related  macular  degeneration (AMD).  These  deposits, 
called drusen,  are found beneath the basement  membrane of  the retinal 
pigmented epithelium (RPE) and the inner collagenous layer of the Bruch 
membrane  (Bm). Despite  the  well-established  correlation  between  the 
presence of drusen and AMD, the underlying cause of drusen formation 
and  its  role  in  RPE  and  photoreceptor  cell  degeneration  are not  fully 
understood (1-3).
 Recent  evidence suggests that  drusen formation and AMD share some 
similarities  with  amyloid diseases  such as  Alzheimer  disease (AD) and 
Parkinson  disease  (PD).  Like  AMD,  amyloid  diseases are  strongly 
correlated with advancing age and the formation of deposits. Moreover, 
these amyloid deposits contain a wide range of lipids and proteins, many of 
which are also present in drusen. Shared components of amyloid deposits 
and drusen include proteins such as vitronectin, amyloid P, apolipoprotein 
E, and even the amyloid ß (Aß) peptide that is associated with amyloid 
plaques  in  AD  (4-6).  In  humans,  the APOE*4 allele  shows  a  strong 
positive association with AD. Interestingly, expression of the APOE*4 
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allele in transgenic mice leads to ocular changes that mimic the pathology 
associated  with  human AMD  (7).  In  addition,  acute  phase  reactants, 
complement  components, immune  modulators,  and  other  inflammatory 
mediators are present in amyloid deposits as well as in drusen, suggesting a 
possible common role for the inflammatory pathway in AMD and amyloid 
diseases  (8-10).  It  is  particularly  noteworthy  that  the  presence of 
complement components such as C5, C5b9 and C3 fragments had been 
observed in drusen of varying sizes and shapes, from small, "hard" drusen 
to large, "soft" drusen, in aging eyes as well as in AMD eyes (9-11). These 
observations are consistent with the idea that complement activation may 
be involved in drusen biogenesis. Together with the recent discovery that a 
polymorphism in complement factor H increases the risk factor of AMD 
(12-15), substantial attention is now focused on the role of inflammation in 
the pathogenesis of this disease.
 Despite the shared similarities mentioned above, AMD has thus far not 
been classified as an amyloid disease. Among the principal differences is 
the fact that classical amyloid diseases typically exhibit large amounts of 
amyloid fibrils  (16).  For example, in the case of  AD, the characteristic 
plaques  consist  primarily of  fibrillar  Alzheimer  Aß  peptide,  while  the 
Lewy bodies  found  in  PD  are  abundant  in  -synuclein  fibrils.  These 
amyloid  fibrils  are  elongated,  6-  to  15-nm-wide  rod-like  structures of 
indeterminate length that are characterized by a common cross ß structure 
(17). In addition to their related structural features, amyloid fibrils display 
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characteristic  tinctorial properties,  such  as  thioflavin  T  and  congo  red 
staining (18-20). Though drusen do stain with thioflavin T and congo red, 
the characteristic apple-green birefringence often seen in congo red–stained 
amyloid fibrils is not present (5, 6). Although amyloid proteins such as the 
Aß peptide, transthyretin, immunoglobulin light chains, and amyloid A are 
found in drusen and sub-RPE deposits (4-6,  9,  21), electron microscopy 
studies have yielded sparse evidence of the presence of bona fide amyloid 
fibrils. These observations have precluded AMD from being viewed as a 
classical amyloid disease.
 Amyloid  fibril  formation  is  a  multistep  protein  misfolding  cascade of 
molecular  events,  wherein  a  monomeric  protein  undergoes  a 
conformational  reorganization  into  a  number  of  different  oligomeric, ß 
sheet–containing structures that ultimately convert into amyloid fibrils (22, 
23).  Numerous  studies  of  various amyloid  diseases  have  led  to  the 
perception that nonfibrillar oligomers, rather than amyloid fibrils, might be 
the primary toxic agents (23-30). This notion has been supported by animal 
models demonstrating that amyloid fibrils do not seem to be required for 
the pathogenesis of amyloid diseases (30-34). These results suggest that 
additional  amyloid  diseases  might  be  identified wherein  pathogenic 
nonfibrillar oligomers are present without considerable accumulations of 
amyloid  fibrils.  Recent  evidence suggests  that  desmin-related 
cardiomyopathy may be such a disease (35).       The central goal of the 
present study was to investigate whether nonfibrillar amyloid oligomers 
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are present in drusen. To address this question, we took advantage of a 
recently  developed  A11 "anti-oligomer"  antibody  that  specifically 
recognizes nonfibrillar oligomers (24). Although this antibody was initially 
raised against a molecular mimic of nonfibrillar oligomer made from the 
Alzheimer Aß peptide, it has been shown to also detect toxic oligomers 
made  from  a  variety  of  other  amyloidogenic proteins  (24)  such  as  -
synuclein,  islet  amyloid  polypeptide (IAPP),  prion  106–126  peptide, 
polyglutamine,  lysozyme, human insulin,  and,  as recently demonstrated, 
the  yeast  prion protein  (36).  Remarkably,  this  antibody  does  not  show 
reactivity (as  demonstrated  by  dot  blots  and  ELISA)  with  soluble 
monomeric protein,  soluble  low–molecular  weight  oligomers,  or  fibrils 
(24).  It  has  been  suggested,  therefore,  that  the  nonfibrillar amyloid 
oligomers from different proteins exhibit common structural features (24). 
Notably,  the  antibody  also  exhibits  a  strongly protective  effect  against 
oligomer-induced toxicity, indicating that oligomers do indeed represent a 
toxic species (24).
 The  utility  of  this  generic  anti–amyloid  oligomer  antibody has  been 
established in immunocytochemical studies as well. For example, through 
this antibody, the presence of nonfibrillar oligomers has been demonstrated 
in AD-affected brains (24). These toxic oligomers were found to be in 
close  proximity  to senile  plaques,  yet  they  have  shown  a  distinct 
localization from the fibrillar plaque region, perhaps indicating the initial 
stage of amyloid fibril deposition (24). Furthermore, the same antibody 
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was used in immunocytochemical studies to identify amyloid oligomers in 
the above-mentioned study on desmin-related cardiomyopathy (35).
In the present study, by using the anti-oligomer antibody, we detected the 
toxic  oligomers  within  drusen-containing donor eyes  but  not  in  control 
eyes without drusen. The presence of amyloid oligomers suggests that the 
underlying  pathogenesis in  AMD  could  be  related  to  that  of  amyloid 
diseases. 
Results
 Immunofluorescent  microscopy  revealed  the  presence  of  amyloid 
oligomers  in  distinct  areas  of  eyes  that  contained  drusen.  Antibody 
reactivity was most frequently observed centrally within drusen, wherein 
the fluorescent signal typically accumulated in close proximity to the inner 
collagenous  layer  of  the  Bm  and  formed a  distinct  subdomain.  These 
structures,  which  we  refer  to  as amyloid  oligomer  cores,  did  not  vary 
appreciably in size, even as the size of the drusen varied. In the smallest 
drusen (<20 µm), the amyloid oligomer cores comprised the majority of the 
drusen content (Figure 1, A and B). In larger drusen, the cores remained at 
approximately 15 µm in diameter and retained the same spatial 
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relationship,  abutting  the  Bm whether  they  had the appearance of  hard 
drusen (Figure 1, C–F) or macular soft drusen (Figure 1, G and H). While 
many of the cores were spherical (e.g., Figure 1, B and D), others appeared 
more elongated in shape (e.g., Figure 1, F and H). These data suggest that 
the oligomer cores may occur at an early point during drusen biogenesis 
but do not appear to grow as drusen become larger. 
Although the size of the amyloid oligomer cores appeared to be restricted, 
the number of cores per druse did vary. Larger drusen in particular were 
sometimes observed to contain several amyloid oligomer cores (Figure 2, 
A,  B,  and  I),  suggesting  that these  drusen  may  have  formed  from  a 
coalescence  of  smaller  drusen. While  not  all  drusen  were  observed  to 
contain amyloid oligomer cores, given the small size of the cores relative 
to the larger drusen, many were likely to be out of the plane of section and 
thus not detectable. Table 1 summarizes the results obtained from the eyes 
of  19  individuals.  Strikingly,  anti-oligomer  antibody reactivity  was 
observed in all eyes that contained drusen, but was not observed in eyes 
from age-matched controls  or  from those of  young donors  that  did not 
contain  drusen.  These  data  establish a  direct  correlation  between  the 
presence of amyloid oligomers and drusen and suggest a possible role for 
oligomer cores in drusen biogenesis. 
Besides the presence of amyloid oligomer cores within drusen, oligomer 
staining was also observed at the Bm in some cases, especially where it 
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appeared to be thickened (Figure 2, C and D) and below the Bm in basal 
linear deposits (Figure  2, E–H). Occasional staining within the RPE was 
also observed (Figure 2H). Staining was not observed in the neural retina 
(data  not shown).  Thus,  antibody  reactivity  is  also  associated  with 
additional pathological changes that are characteristic of AMD. 
Specificity of the anti-oligomer antibody is exhibited in Figure 2, I and J, 
which  depict  serial  sections  obtained  from the  same druse.  This  druse 
contained several foci of anti-oligomer reactivity (Figure 2I). Staining was 
not  seen when the section  was incubated without  the  primary antibody 
(data  not  shown),  nor  when  the antibody  was  preincubated  with 
nonfibrillar oligomers made from the Aß1–40 peptide (Figure 2J). It should 
be noted that the nonfibrillar oligomers made from Aß1–40 and Aß1–42 are 
structurally similar  with regard to their  immunoreactivity  with the anti-
oligomer antibody and their cellular toxicity (24). The difference lies in the 
kinetics of their formation: Aß1–42 forms oligomers on a faster time scale 
than does Aß1–40 (24, 37). We performed ELISA in order to further test the 
specificity of the anti-oligomer antibody in tissue homogenates prepared 
from  the  neural  retina  or  from  the  underlying  tissue  containing 
drusen/RPE/Bm. In vitro synthesized nonfibrillar Aß1–40 oligomers served 
as a positive control. As shown in Figure 3A, a dose-dependent reactivity 
to increasing amounts of Aß1–40 oligomers was observed in the presence of 
the oligomer-specific antibody, but not when the antibody was omitted. 
Comparisons of antibody reactivity were also made between extracts 
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prepared from  the  neural  retina  and  from  the  tissue  containing 
drusen/RPE/Bm (Figure  3B).  A dose-dependent  reactivity was observed 
with extracts prepared from drusen-containing tissue, whereas no reactivity 
was observed in the absence of the primary antibody. Little reactivity was 
observed with extracts prepared from the neural retina of the same donor 
eye. Thus the positive signal seen in drusen appears to be highly specific 
for amyloid oligomers. 
The data presented thus far support the notion that amyloid oligomers are 
present  in  drusen.  Further  inspections  of  the sections  at  higher 
magnifications  using  laser  scanning  confocal microscopy  revealed  a 
punctate  pattern  of  small  vesicular  structures that  increased  in  density 
toward the center of the amyloid oligomer core (Figure 4A). Occasionally, 
a decreasing gradation of the punctate pattern appeared to extend toward 
the  RPE  (Figure  4B). In  other  instances,  the  vesicular  structures  were 
observed to penetrate through the layers of the Bm (Figure 4C). Together, 
these data suggest that the amyloid oligomers could be trafficked between 
the RPE cells, the drusen, and the choroid. 
In order to confirm the vesicular nature of the cores, we first used indirect 
immunofluorescence  to  identify  a  druse  that  contained an  amyloid 
oligomer  core.  An  adjacent  serial  section  was  then prepared  for 
immunogold labeling, followed by electron microscopy (Figure  4D). As 
judged by distribution of the gold particles, these studies did indeed verify 
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that  the  amyloid  oligomers  were associated  with  vesicular  structures. 
Again, these vesicular structures appeared to be more concentrated near the 
Bm, although similar structures were occasionally labeled within the apical 
aspect of the druse closer to the RPE as well (data not shown). 
The structures of the amyloid oligomer cores appear to be similar in some 
respects  to  dendritic  cell  processes,  as  reported  by Hageman et  al.  (8). 
Double  staining  with  the  anti-oligomer  antibody (green,  FITC)  was 
performed in conjunction with anti–HLA-DR (red, Texas red) in order to 
determine  whether  the  immunoreactivities colocalized  (Figure  5,  A–D). 
Strong  HLA-DR reactivity was  seen  within  the  drusen  (Figure  5B)  or 
beneath the Bm, where it appeared to penetrate into the druse and come 
into close proximity to the oligomer core (Figure 5C) and even completely 
surround it (Figure 5D). In some instances, HLA-DR reactivity appeared to 
be in  close proximity to  the amyloid oligomer core (Figure  5B).  Upon 
closer inspection, it was clear that the immunofluorescent signals did not 
overlap (Figure 5, C and D). Thus the amyloid oligomer cores are distinct 
structures from the HLA-DR–positive dendritic  cell  processes described 
above. 
Double  staining  was  also  performed  on  drusen  sections  to  visualize 
oligomer  cores  and  vitronectin,  an  acute  phase  protein  that is  a  major 
component of drusen (38) (Figure  5, E–H). All drusen stained positively 
for vitronectin, whereas oligomer cores were present only in a subset of 
drusen (e.g., Figure 5F). Vitronectin tends to have heterogeneous labeling 
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patterns. In  drusen  that  reacted  positively  for  both  oligomer  cores  and 
vitronectin, no overlap in their signals was observed. To ascertain whether 
the  oligomer  cores  are  assembled  from Aß, sections  containing  drusen 
were  costained  for  these  2  components (Figure  5,  I–L).  Most  drusen 
contained  either  the  Aß assemblies  or  oligomer  cores,  but  not  both. 
Consistent  with previous  reports,  Aß  reactivity  was  associated  with 
vesicular  structures  within drusen (Figure  5,  K and L).  In  1 druse that 
reacted with both antibodies, the fluorescent signals did not colocalize: the 
amyloid oligomer reactivity was associated with the RPE, whereas the Aß 
reactivity decorated spherical structures within the druse (Figure 5L). Thus 
amyloid oligomers do not appear to colocalize with many of the known 
drusen components. 
Different tissue or cultured cell types show varying susceptibility to the 
toxicity  of  amyloid  aggregates  (39).  We  sought  to  examine whether 
amyloid oligomers are toxic to RPE cells, given their close proximity to 
each other in eyes that contain drusen. As expected, oligomeric, but not 
soluble monomeric, IAPP and  -synuclein exerted toxicity toward human 
primary RPE cells and SH-SY5Y human neuroblastoma cells (Figure 6A). 
Similarly, oligomers made from Aß1–40 were toxic to human primary RPE 
cells  in  culture.  This  toxicity  was  largely  blocked  when the  A11 anti-
oligomer antibody was included in  the incubation mixture  (Figure  6B). 
These  results  confirm  that  nonfibrillar oligomers  made  from 
amyloidogenic protein and peptides are toxic to human primary RPE cells. 
Thus, the presence of amyloid oligomers in close proximity to RPE cells 
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may have a negative impact on the physiology of these cells during drusen 
biogenesis and in AMD.
Discussion
 
Nonfibrillar  oligomeric structures  made from amyloidogenic proteins or 
peptides are thought to contribute to the pathogenesis of amyloid diseases. 
Such structures  can  be detected in  tissue sections  in  situ  by a  recently 
developed conformation-specific, but not sequence-specific, antibody (24). 
Through the use of this antibody, we demonstrated the presence of amyloid 
oligomers in  drusen-containing eyes  and eyes  that  have  been  clinically 
diagnosed with atrophic AMD. Importantly, no reactivity was observed in 
control eyes without drusen, which suggests that the formation of amyloid 
oligomers  is  a  disease-specific  process. Since  nonfibrillar  amyloid 
oligomers  demonstrated  toxicity  toward cultured  primary  human  RPE 
cells, they may contribute to their demise during the disease process. Thus, 
AMD and  amyloid  diseases appear  to  share  similar  protein  misfolding 
events  and  may  share common  pathogenic  pathways  as  well. 
One commonality is the discovery that spherical Aß assemblies as well as 
other proinflammatory proteins  commonly seen in AD plaques are  also 
present in drusen (9, 10). In particular, Anderson et al. showed that a single 
druse may contain no Aß structures or a large number of them, ranging in 
diameter from 0.25 to 10 µm and displaying highly organized concentric 
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layers  when  viewed  under  an  electron  microscope  (5).  Thus,  the Aß 
assemblies reported by Anderson et al. are structurally distinct from the 
oligomer-associated vesicles  due to differences in their  size,  shape,  and 
distribution. Indeed, our data show that they did not colocalize in drusen. It 
is  important  to  note, however,  that  the  epitope  for  Aß may have  been 
masked within the oligomeric structure, as is the case when Aß monomers 
are transformed into amyloid fibrils (40). Therefore, we cannot preclude 
the possibility  that  the  oligomeric  cores in  drusen are  made up of  Aß. 
Another drusen subdomain, described by Mullins and Hageman (41),  is 
composed of core-like structures that exhibit  Arachea hypogea agglutinin 
reactivity. Although  these  structures  to  some  extent  resemble  the 
oligomeric structures described herein, they range in diameter from 5 to 38 
µm,  whereas  the  amyloid  oligomer  cores  are  typically 10–15  µm.  It 
appears  then  that  the  oligomeric  structures discussed  here  differ 
distinctively from the substructures within drusen that had been described 
previously. Composition of the oligomeric structures within drusen has yet 
to be determined and is under investigation. Our data have yielded further 
evidence  that  AMD  and  amyloid diseases  share  common  pathogenic 
pathways,  although  amyloid fibrils  have  not  been  observed  in  drusen. 
Amyloid  protein–related toxicity  in  the  absence  of  fibrils  had  been 
observed in the past. For example, in a transgenic mouse model for AD, 
overexpression of the human wild-type ß-amyloid precursor protein leads 
to learning deficits and Aß deposition without amyloid plaque formation 
(42). In the case of a mouse model for PD, it has been shown that 
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overexpression of wild-type -synuclein results in motor abnormalities and 
the  formation  of  -synuclein–containing, nonfibrillar  inclusions  (43).  In 
transgenic rats expressing human IAPP that served as an animal model for 
type 2 diabetes, apoptosis of pancreatic islet cells did not correlate with 
amyloid formation (33). These results indicate that the presence of amyloid 
fibrils  is  not  a  prerequisite  for  pathogenesis  and  implicate the  toxic 
nonfibrillar oligomers as an underlying cause of cell loss (30). Thus, AMD 
and desmin-related cardiomyopathy (35) might be just 2 of several diseases 
that are related to amyloid diseases, yet do not exhibit noticeable amyloid 
fibril  deposition. Although  it  is  not  obvious  why  amyloid  fibrils  are 
difficult to detect  in drusen,  the rate at  which oligomers and fibrils are 
turned over are likely to be of importance. As mentioned above, amyloid 
fibril formation is a stepwise process, and the overall yield of oligomers 
and  fibrils  depends  upon the  underlying kinetics  of  each  step.  Thus,  2 
possible explanations for the low degree of fibril deposition are slow rates 
of  fibril  formation or  fast  rates  of  clearance.  It  is  known that  rates  of 
amyloid fibril formation are largely dictated by experimental conditions, 
and biochemical data suggest that under appropriate conditions the stability 
of oligomers can be maintained for extended periods of time (44, 45). The 
stability  of  the  oligomers  in  the  drusen may also be  stabilized through 
interacting with other proteins. In addition, it is conceivable that oligomers 
might be cleared out of drusen before they can be converted into fibrils. 
Although the present study provides no direct evidence of such clearance, 
the ability of oligomeric structures to penetrate through the Bm suggests 
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this possibility.
Recent immunocytochemical data on HLA-DR reactivity in drusen suggest 
the presence of dendritic cell processes in drusen (8). Dendritic cells are 
antigen-presenting cells that take up foreign substances and, in principle, 
may  facilitate  the  clearance  of amyloid  oligomers.  Indeed,  our  studies 
show the presence of HLA-DR–reactive structures in drusen similar to that 
reported by Hageman et  al.  (8).  These putative dendritic  cell  processes 
appear  more  frequently  in  and  around  the  drusen  than  the  amyloid 
oligomers,  and  they  were  sometimes  found  in  close  proximity to  the 
amyloid  oligomer  cores.  They  do  not,  however,  appear to  colocalize. 
Future studies should enable us to determine whether a relationship exists 
between the dendritic cells and the amyloid oligomer cores. Our data add to 
the growing list of evidence that reveals similarities between AMD and 
amyloid diseases (4-7). It is particularly noteworthy that proinflammatory 
proteins have been identified in the extracellular deposits associated with 
these  diseases.  Evidence  of  complement activation  has  been  observed 
within  certain  RPE cells,  small drusen,  and  large,  soft  drusen  that  are 
present in aging eyes as well as in AMD eyes (10). This observation has 
led to the hypothesis that aberrant immune reactions may play a role in 
drusen biogenesis.  Notably, a polymorphism in complement factor H, a 
key regulator of complement activation, has recently been identified as a 
major risk factor for AMD (12-15). This finding has placed a significant 
focus on the role of complement activation in the pathogenesis of AMD: 
what are the factors that lead to the activation of the immune response? 
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Here we report the presence of amyloid oligomers in a similar distribution 
of  drusen,  RPE cells,  and  basal  deposits.  It  is  noteworthy  that  these 
oligomers have been implicated in the pathogenesis of amyloid diseases 
due  to  their  demonstrated  toxicity  toward  cells.  It  is  possible that  the 
presence of oligomers in close proximity to RPE cells may compromise 
their  function,  leading  to  activation  of  the complement  cascade  and 
formation of drusen.
In summary, the presence of amyloid oligomers in drusen suggests that 
AMD and amyloid diseases share commonalities with respect to protein 
misfolding  and  pathogenesis.  AMD and  desmin-related cardiomyopathy 
(35)  may  well  come to  represent  the  first  examples of  a  new class  of 
amyloid  disease  in  which  oligomeric  intermediates, rather  than  mature 
amyloid fibrils, accumulate. 
Methods
 
Human tissue. Intact human donor eyes were obtained from the Oregon 
Lions Sight and Hearing Foundation and the Alzheimer Disease Research 
Center  (ADRC)  Neuropathology  Core  of  the  University  of  Southern 
California.  Eyes  from  19  individuals  were  examined,  4  of  which had 
documented clinical histories of AMD (Table 1). All eyes were kept at 4°C 
and processed at less than 24 hours postmortem. Fixation was avoided 
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since  it  would  have  interfered  with  antigen detection  using  the  anti-
oligomer–specific  antibody.  After removing the anterior  pole,  the retina 
was peeled off and the posterior pole of the eyeball was examined under a 
dissecting microscope (MZ125; Leica Microsystems) for the presence of 
drusen. All areas containing drusen were included. Tissue was cut into 1-
cm x 0.5-cm rectangles,  using a  coated stainless  steel  razor blade,  and 
embedded in OCT (Tissue-Tek; Sakura Finetech). 
Confocal immunofluorescence microscopy. Frozen embedded tissue was 
sectioned on a cryostat (CM 3050S; Leica Microsystems) at –20°C. Frozen 
sections 8–10 µm thick were collected on precleaned Superfrost plus-slides 
(VWR  International),  air  dried  for  30  minutes,  and  stored  at –20°C. 
Immunocytochemical  studies  using  the  anti-oligomer–specific antibody 
were  performed  as  described  previously  (24).  Briefly, sections  were 
blocked overnight at 4°C in blocking solution (phosphate-buffered saline 
containing 2% BSA and 2% goat serum) and incubated the following day 
with  affinity-purified  anti-oligomer–specific antibody (1.6  mg/ml)  for  1 
hour at room temperature. Sections were then washed and incubated with a 
fluorescein-conjugated goat  anti-rabbit  antibody  (1:100;  Vector 
Laboratories) for 1 hour at room temperature. In order to detect oligomers 
and HLA-DR or drusen components such as vitronectin and Aß, sections 
were processed as described above and incubated with mouse anti-human 
HLA-DR antibody (0.5 mg/ml, BD Biosciences — Pharmingen), mouse 
anti-vitronectin antibody (1:200, BioSource International), or mouse anti-
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Aß antibody  (1:100,  4G8;  Signet  Laboratories Inc.),  which  is  directed 
against residues 17–24 of the Aß peptide. Digital images of immunostained 
sections were  acquired  on  an  LSM  510  Zeiss  laser  scanning  confocal 
microscope. 
Electron microscopy. Prefibrillar oligomers were first identified in frozen 
sections using  immunofluorescence.  Adjacent  serial  sections  known  to 
contain  oligomers  were  incubated  with  the  anti-oligomer  antibody, and 
subsequently  with 5  nm gold-conjugated goat  anti-rabbit antibody (Ted 
Pella Inc.). The sections were washed and pre-embedded in 4% agarose. 
Agarose-embedded sections were then briefly fixed in OsO4, dehydrated in 
increasing  concentrations  of  ethanol, infiltrated  with  epoxy  resin,  and 
sectioned  at  70  nm  using  an ultramicrotome  (Ultracut  UCT;  Leica 
Microsystems)  for  electron microscopy.  Images  were  obtained  using  a 
transmission electron microscope (EM10; Zeiss). 
Preparation  of  soluble  A  ß  oligomers. Aß oligomers  were  prepared  as 
described previously (26).  Briefly,  1.0  mg Aß was dissolved in  400 µl 
1,1,1,3,3,3-hexafluoro-2-propanol  (HFIP)  for  10  minutes  at  room 
temperature.  Aliquots  (100  µl)  of  the  solution  were  added to  900  µl 
double-distilled H2O in siliconized Eppendorf tubes. After 10 minutes of 
incubation the samples were centrifuged for 15 minutes at 14,000  g, and 
the  supernatant  fraction  was transferred  to  a  new siliconized  tube.  The 
HFIP was evaporated by blowing under an N2 stream for 5–10 minutes. 
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The samples were then stirred at 500 rpm using a Teflon coated micro stir 
bar for 24–48 hours at room temperature. Aliquots were taken at 6- to 12-
hour intervals to check for the presence of spherical oligomers. 
ELISA. ELISA was  performed  with  tissue  homogenates  and  oligomers 
made from the Aß peptide. To process eye tissue samples, neural retina was 
peeled off the underlying RPE/Bm/choroid complex at the posterior eye 
pole.  Isolated  tissues  (neural  retina  or the  underlying  RPE/Bm/choroid 
complex) were homogenized using a tip sonicator (Microson) in double-
distilled H2O and centrifuged, and supernatant was collected. ELISA was 
performed  using  the anti-oligomer–specific  antibody  as  described  by 
Kayed and colleagues (24). Briefly, samples were diluted in coating buffer 
(0.1 M sodium bicarbonate) and added to wells of a 96-well microplate 
(BD). After 2 hours of incubation at 37°C, samples were blocked for 2 
hours at 37°C with 3% BSA tris-buffered saline with 0.1% Triton X-100. 
Anti-oligomer antibody (100 µl, 1:2500) was added and incubated at 37°C 
for  1  hour,  prior to  incubation  with  100 µl  of  horseradish  peroxidase–
conjugated anti-rabbit IgG for 1 hour at 37°C. Subsequent to development 
with 3,3',5,5'-tetramethylbenzidine, the reaction was stopped with 100 µl 1 
M  HCl,  and  plates  were  read  at  450  nm  (Benchmark Plus;  Bio-Rad 
Laboratories). 
Cell  viability  assay. Cell  viability  was  assessed  spectrophotometrically 
using a 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide–
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based (MTT-based) assay (Sigma-Aldrich). RPE cells isolated from human 
fetal eyes were obtained from Advanced Bioscience Resources Inc. The 
cells were maintained in DMEM supplemented with 2 mM L-glutamine, 
100 U/ml penicillin, 100 µg/ml streptomycin, and 10% fetal bovine serum 
at 37°C. Third to fourth passage cells were seeded at 10,000 cells per well 
in  a  96-well  plate  and  grown  for  3–4  days to  approximately  90% 
confluence.  SH-SY5Y  human  neuroblastoma cells  were  maintained  in 
DMEM with 10 nM HEPES, 10% fetal bovine serum, 4 mM glutamine, 
penicillin (200 U/ml), and streptomycin (200 µg/ml) in 5% CO2 at 37°C. 
They were differentiated and plated as previously described (24). Prior to 
the toxicity assay, media was replaced with indicated concentrations of Aß 
oligomers alone or with equal molars of the A11 anti-oligomer antibody 
dissolved in phenol red–free DMEM. The conditions were carried out in 
triplicate. After 4 hours, MTT dissolved in DMEM was added to the cells 
and incubated for an additional 4 hours. Insoluble crystals were dissolved 
by adding MTT solubilization solution (10% Triton X-100, 0.1 N HCl in 
anhydrous isopropanol), and absorbance was measured at 570 nm. 
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Figure 1
Immunolocalization of amyloidogenic oligomers in drusen by confocal laser microscopy. (A, C, E, 
and G) Differential interference contrast images. (B, D, F, and H) Confocal fluorescence images of 
amyloid oligomer cores (green, FITC channel). Drusen exhibit amyloid oligomer reactivity in the 
form of a core-like structure that accumulates centrally within drusen and in close proximity to the 
Bm. Autofluorescence of lipofuscin granules in the RPE cytoplasm is shown in red (Cy3 channel). 
(A and  B) Anti-oligomer–specific antibody recognizes a spherical structure ( 15 µm) in a small 
druse ( 30 µm). (C–F) Two larger drusen with centrally located core structure. (G and H) A very 
large macular soft  druse from an 81-year-old female donor. Despite the difference in sizes and 
shapes of the drusen, the amyloid oligomer cores remain 10–15 µm in size. Scale bars: 10 µm.
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Figure 2
Presence  of  amyloid oligomers  in  drusen  and thickened Bm.  Amyloid oligomer  reactivity  was 
visualized with fluorescein (green), and lipofuscin autofluorescence was visualized using the Cy3 
channel (red). Multiple amyloid oligomer cores were sometimes observed in large drusen (A and 
B), as if a large druse may have formed from the fusion of several smaller drusen. The amyloid 
oligomer cores retained their size and relative positions within the druse and in proximity to the 
Bm. Within eyes that contained drusen, the oligomers occasionally accumulated above the Bm, in 
the form of basal linear (C and D) or basal laminar (E–H) deposits, particularly in instances where 
the Bm appeared to be thickened. (H) Staining within RPE cells was also observed.  C and D are 
differential  interference  contrast  images  of  D and  F,  respectively.  (I and  J)  Specificity  of  the 
antibody in cryosections is demonstrated in adjacent sections of a large druse. (I) Multiple amyloid 
oligomer  cores  were  visualized  through  use  of  the  anti-oligomer  antibody.  (J)  Reactivity  was 
eliminated when the primary antibody was preincubated with amyloid oligomers synthesized from 
the Aß1–40 peptide. Scale bars: 10 µm.
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Figure 3
ELISA  of  retinal  extracts  using  the  A11  anti-oligomer  antibody.  (A)  Increasing  amounts  of 
oligomers made from the Aß1–40 peptide resulted in a dose-dependent response when incubated with 
the A11 anti-oligomer–specific antibody (filled circles). Little or no reactivity was observed when 
the  Aß1–40 oligomers  were  incubated  without  the  primary  antibody  (open  circles).  (B)  Dose-
dependent reactivity was observed when the A11 antibody was incubated with increasing amounts 
of extract prepared from dissected drusen/RPE/Bm tissue from a 76-year-old male donor (filled 
circles). Little or no reactivity was observed when the primary antibody was omitted (open circles). 
Extracts prepared from the neural retina (filled triangles) of the same donor eye did not show a 
dose-dependent response when incubated with the A11 antibody. Dr, drusen.
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Figure 4
Morphology  of  amyloid  oligomer  cores  in  drusen  at  higher  magnification.  (A–C)  Confocal 
micrographs of drusen. Amyloid oligomer cores are labeled with fluorescein (green), and lipofuscin 
autofluorescence  in  the  RPE  is  visualized  in  red  (Cy3  channel).  (A)  Amyloid  oligomer  cores 
seemed to  consist  of  an  aggregate  of  small  vesicular  structures  (arrowheads)  that  increased  in 
density toward the center. (B) Some of these vesicular structures appeared to extend toward the 
RPE  with  diminishing  density  (arrowheads).  (C)  Occasionally,  the  amyloid  oligomer  cores 
penetrated through the Bm and extended toward the choroid (arrowhead). (D) Ultrastructure of an 
amyloid oligomer core is depicted in an immunogold-labeled electron micrograph (inset), wherein 
gold particles decorate vesicular structures that are heterogeneous in size. The highest density of 
gold particles seen in  D was from the region above the Bm (rectangle). Scale bars: 100 nm (D, 
inset). Magnification, x3,000 (A), x2,000 (B–D).
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Figure 5
Codistribution  of  amyloid  oligomer  cores  and  other  known drusen  components.  (A,  E,  and  I) 
Differential  interference contrast  images.  (B–D,  F–H,  and  J–L)  Confocal  fluorescence images; 
amyloid  oligomer  cores  were  labeled  with  fluorescein  (green).  (A and  B)  Both  antigens  were 
present in a large druse, wherein the amyloid oligomer core was enveloped within the HLA-DR 
reactive region (labeled with Texas red). (C and  D) At higher magnification, it is clear that the 
amyloid oligomer core and HLA-DR reactive subdomain did not colocalize in these drusen. (C) In 
one instance, the HLA-DR reactive region, perhaps reflecting a dendritic cell process, was observed 
as originating from the choroid (Ch), coming in close proximity to the Bm, and contacting the 
condensation  of  vesicular  structures  that  represent  the  amyloid  oligomer  core.  (D)  In  another 
instance, HLA-DR reactivity was observed as encompassing the choroid, the Bm, and the druse. 
Within the druse, HLA-DR reactivity appeared to surround the oligomer core, with no indication of 
colocalization. Similarly, no colocalization was observed with vitronectin (F–H) or Aß (J–L), both 
labeled with Texas red (red). Lipofuscin autofluorescence within RPE is also visualized in the Cy3 
channel (red). Scale bars: 10 µm. Magnification, x250 (E, F, I, and J), x1,500 (G), x1,000 (H), and 
x2,000 (K and L).
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Figure 6
 
Toxicity of nonfibrillar amyloid oligomers to human primary RPE cells. (A) Amyloid oligomers 
were toxic to cultured SH-SY5Y human neuroblastoma cells (white bars) and human primary RPE 
cells (black bars). Oligomeric forms of IAPP and -synuclein ( -Syn), but not soluble monomers, 
demonstrated toxicity. Cell viability was assessed by MTT reduction. (B) Increasing amounts of 
amyloid oligomers made from Aß1–40 also showed a dose-dependent toxicity to cultured human 
primary RPE cells (black bars). This toxicity was largely blocked by adding equal molars of the 
A11 anti-oligomer antibody (white bars). Error bars represent SD; n = 3.
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Future Prospects
This  study  demonstrates  a  direct  correlation  between  the  appearance 
ofdrusen and the existence of toxic oligomers in eyes with Age-related 
Macular Degeneration (AMD). Nineteen donor eyes were tested for the 
existence  of  toxic  oligomers  in  the  neural  retina  through  use  of  a 
conformational  dependent  anti-oligomer  antibody  (1).  Toxic  oligomers 
were found in all eyes with drusen (fourteen eyes) as well within drusen as 
in  close  proximity  to  retinal-pigmented  epithelial  cells  (RPE)  that  are 
known  to  degenerate  in  the  process  of  AMD.  Contrary,  eyes  without 
drusen (five eyes) had no signs of oligomer existence.  As well eyes of 
comparable donor age (two eyes) as eyes of younger donors (three eyes) 
were oligomer negative, which conclusively eliminates the possibility of 
age-correlation and emphasizes the possible importancy of toxic oligomers 
in the pathogenesis of AMD. In order to evaluate the results of this study it 
is important to note, that
• the underlying cause of AMD is still unknown, even if new studies
   indicate an inflammatory process as a crucial part of AMD
   pathogenesis (2),
•  drusen, dependent on size and frequency, are seen as the first
   indication of AMD-development (3),
•  the discussed oligomers represent a specific protein structure that are a
    result of a protein missfolding process and are seen as a primary
    pathogen for clinical symptoms (4) and degenerative tissue processes
    in protein missfolding disorders (PMDs) (5).
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Therefore is the indication of a direct correlation between toxic oligomers
and  drusen of  highest  interest  in  double  respect  and will  be  following 
discusssed on the basis of our results.
1. Indication of a possible protein missfolding process in the pathogenesis 
of AMD
and therefore possible transfer of knowdledge from in vitro and in vivo
PMDs-studies to AMD:
A) Protein-Idendity
B) RPE cells as a source of toxic oligomers
C) RPE cells represent a target for toxic oligomers
D) Oligomers and the immunesystem in respect to the pathogenesis of
PMDs and AMD
2. Indication of a primary pathogen for a degenerative process in AMD
and therefore new therapeutic and prophylactic strategies for AMD with
toxic oligomers as a primary target
1. Indication of a possible protein missfolding process in the pathogenesis 
of AMD
A) Protein-Idendity
The fact that each PMD seems to be based on the missfolding of one 
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particular  protein (for  example the aβ-peptide in  Alzheimers,  the  IAPP 
peptide in Diabetes Typ II or the α-synuclein protein in Parkinsons leads to 
the question of the protein-idendity of oligomers in drusen (6). This study 
could not answer this question, since the specific anti-oligomer antibody 
recognizes exclusively a oligomeric structure of numerous PMDs-related 
proteins, but not the aminoacid sequence of a particular protein (1).   
The  approach  of  double-labeling  with  the  conformational-dependent 
antioligomer  antibody  and  different  aminoacidsequence-dependent 
antibodies  that  are  directed  against  the  aminoacidsequence  of  the 
prominent drusen protein vitronectin or the Alzheimers-related aβ-peptide 
was without success. 
Of course one possibility cannot be excluded. The change of conformation 
from a monomeric to a oligomeric structure may mask the epitope of the 
proteins and inhibits therefore the recognition through aminoacidsequence-
dependent antibodies (7).  Furthermore, in vitro studies demonstrate that 
even proteins,  which are  so far  not  to  be known to be disease-related, 
could underlie a similar protein missfolding process (8, 9) that is observed 
with  proteins  of  PMDs.  Therfore  all  drusen  proteins  (10)  may  be 
considered as a possible candidate. The idendity of the protein is of highest 
interest, since most neurodegenerative diseases have a genetic background 
with  mutations  of  the  missfolded  protein  (prion-mutations  in  the 
Gerstmann-Straussler  syndrome or  hereditary  Creutzfeldt-Jakob disease, 
taumutations  in  autosomal  dominant  dementia  and  alpha-synuclein-
mutations in autosomal dominant Parkinsons) or mutations of their 
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precursor  protein  (APP in  Alzheimers)  (11).  Further  studies  with  laser 
capture microscpy or immuno- precipitation and mass spectometry may 
help  to  answer  this  central  question  of  the  protein-idendity  of  the 
oligomeric structures within drusen.
B) RPE cells as a source of toxic oligomers
A  recent  Prion-disease  study  suggested,  that  the  missfolded  protein  is 
released  through  vesicles  (exosomes)  into  the  extracellular  space  after 
fusion with the cell membrane (12). Therefore someone can only speculate 
if RPE cells could be the source of the monomeric or oligomeric protein in 
the  case  of  AMD,  but  the  massive  existence  of  oligomers  in  close 
relationship  to  RPE  cells  may  emphasize  this  suspicion.  Furthermore, 
immunofluorescence  microscopy  demonstrates  oligomers  in  vesicular 
form or bound to vesicles in drusen. Interestingly, these vesicles can be 
followed back to specific RPE cells and exhibit an average diameter of 100 
nm (electron microscopy result), a size which has been also observed of 
„prion-exosomes“ (12).
Further studies should show, if observed vesicles represent oligomers in 
vesicular form or oligomers that are bound to vesicles (exosomes). The 
size  of  the  observed  vesicles  in  drusen  indicates  the  latter,  because 
oligomers are described in the literature in a much smaller size of 3-10 nm 
(13).  Furtherbapproaches  may  include  vesicle  markers  (MHC  II,  anti-
ganglioside antibodies)
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C)  RPE cells represent a target for toxic oligomers
Our study demonstrates that oligomers are in close proximity to RPE cells,
but not to photoreceptor cells. Therefore only RPE cells may be a primary 
target for oligomer-induced toxicity.  Furthermore we could demonstrate 
that  RPE cells  are successible for oligomer-induced toxicity.  This is  of 
interest, because new studies demonstrated that oligomer-induced toxicity 
may be a cell dependent process relating to their membran composition, 
such as cholesterol (14). Membrane composition may change through age, 
diet,  genetics,  disease  or  development.  Therefore  it  is  important  to 
investigate if the membran composition of RPE cells may differ in age or 
disease,  particular  in  AMD,  which  could  affect  the  oligomer-induced 
toxicity in one or the other way (data not shown).
D) Oligomers and the immunesystem in respect  to  the  pathogenesis  of 
AMD
New studies demonstrate that a chronic inflammatory process may be an 
important key player as well in AMD as in Parkinsons (15), Alzheimers 
(16) and other PMDs (17). It has been shown that specific polymorphismn 
of  particular  mediators  of  the  inflammatory  cascade  are  risk  factors  in 
Alzheimers  (16)  and  Parkinsons  (15).  Interestingly,  a  similar 
polymorphism  regarding  the  factor  H  (HF1)  has  been  recently  also 
observed in AMD (18). Factor H inhibits the complement cascade and 
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therefore  protects  tissue  from  uncontrolled  action  of  the  complement 
cascade. But the question remains open what factor actually triggers or 
activates  the  complement  cascade.  It  is  important  to  note,  that  HF1 
colocolizes with amyloid vesicles in drusen. Even if these vesicles seem to 
differ  from oligomeric  vesicles  described in this  study,  toxic oligomers 
should be considered as an activating factor of the complement cascade 
(19, 20).  Therefore someone can speculate that  toxic oligomers are not 
only responsible for cell death trough direct toxicity, but also exhibit the 
capability  to  activate  the  complement  cascade,  which  might  lead  to 
increased  tissue  damage  in  HF1  polymorphism.  Furthermore,  a 
continously forming process of oligomers without elimination (the rate of 
forming is faster than the rate of eliminating) may result in a continously 
activation of the immune system.
2.: Oligomers as a target for new therapeutic und prophylactic strategies
So far the underlying cause for AMD is unknown. Therefore therapeutic 
strategies are limited and directed against  particular  symptoms, such as 
choroidal  neovascularization,  and  are  applied  in  specific  cases. 
Prophylactic  strategies  are  generell  and  include  advices  regarding  a 
healthy diet (nuts) or environmental behaviour (smoking).
Therefore, the proof of toxic oligomers in AMD-eyes may lead to new
therapeutic strategies with oligomers as a primary target, including drugs
that
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• inhibit the formation of oligomers ( such as the curry-pigment
curcumin, 21)
• inhibit the interaction with membrane components, such as cholesterol
as described above
• neutralize the oligomer-induced toxicity.
Interestingly,  passive  or  active  vaccination  could  already  demonstrate 
some promising success in animal modells of PMDs. Application of small 
doses  of  oligomers  of  the  abeta-peptide  into  AD-mice  resulted  in  the 
production of antibodies that  neuralize the toxicity of oligomers in cell 
cultures (22). A similar effect could be observed trough vaccination with 
oligomerspecific abeta-antibodies (23). Unfortuanetly, the idendity of the 
oligomeric protein in AMD is so far unknown. But with the use of the anti-
oligomer  antibody,  the  idendity  of  the  protein  might  not  even  be  of 
interest,  because  this  antibody is  directed  against  a  toxic  structure  and 
might limit  the risk of the development of antibodies that  react  against 
functional  proteins.  A use of  this  antibody might  be a silver  bullet  for 
therapy  in  all  PMDs  with  oligomers  as  a  primary  target.  Our  results 
indicate that AMD might be a candidate for this therapeutic approach.
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Korrelation zwischen amyloidalen oligomerischen
Proteinstrukturen und Drusen der Alters-bedingten
Makuladegeneration
Summary
Protein  misfolding  and  aggregation  are  thought  to  underlie  the 
pathogenesis  of  many  „amyloid  diseases“,  such  as  Alzheimers  and 
Parkinsons, whereby a stepwise protein misfolding process begins with the 
conversion  of  soluble  protein  monomers  to  prefibrillar  oligomers  and 
progresses  to  the  formation  of  insoluble  amyloid  fibrils.  Drusen  are 
extracellular  deposits  found  in  eyes  afflicted  with  age-related  macular 
degeneration  (AMD).  Recent  characterizations  of  drusen  have  revealed 
protein  components  that  are  shared  with  amyloid  deposits.  However, 
characteristic amyloid fibrils have thus far not been identified in drusen. In 
this study, we tested the hypothesis that nonfibrillar oligomers may be a 
common  link  in  amyloid  diseases.  Oligomers  consisting  of  distinct 
amyloidogenic  proteins  and  peptides  can  be  detected  by  a  recently 
developed  antibody  that  is  thought  to  recognize  a  common  structure. 
Notably, oligomers exhibit cellular toxicity, which suggests that they play 
a role in the pathogenesis of neurodegenerative diseases. Through use of 
the  anti-oligomer  antibody,  we  came  to  observe  the  presence  of 
nonfibrillar,  toxic  oligomers  in  drusen.  Conversely,  no  reactivity  was 
observed  in  age-matched  control  eyes  without  drusen.  These  results 
suggest that amyloid oligomers may be involved in drusen biogenesis and
that similar protein misfolding processes may occur in AMD and amyloid
diseases.
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Zusammenfassung
Protein-Missfaltung  und  Aggregation  können  als  zugrunde  liegende 
Ursache in der Pathogenese von „Amyloidalen Erkrankungen“, wie z.B. 
die  Alzheimersche und Parkinsonsche Krankheit, betrachtet werden. Bei 
diesen ändert sich die Konformation eines Proteins schrittweise von einer 
anfänglichen monomerischen über eine pre-fibrilläre oligomerische bis hin 
zu  unlöslichen  amyloidalen  fibrillären  Struktur  ändert.  Drusen  sind 
extrazelluläre  Proteinablagerungen,  die  sich  in  von  AMD-betroffenen 
Augen finden lassen. Neuere Drusenstudien beschreiben eine Reihe von 
Proteinen,  die  sich  auch  in  amyloidalen  Ablagerungen  finden  lassen. 
Allerdings sind bis heute keine amyloidalen Fibrillen als Bestandteil von 
Drusen entdeckt worden. In dieser Studie testen wir die die Hypothese, 
daβ  amyloidale  oligomerische  Strukturen  eine  Gemeinsamkeit  in 
amyloidalen  Erkrankungen  darstellen.  Interessanter  Weise  besitzen 
oligomerische Proteinstrukturen eine Zelltoxizität, was deren Bedeutung in 
der Pathogenese von neurodegenerativen Erkrankungen unterstreicht. Die 
oligomerische  Struktur  von  verschiedenen  amyloidalen  Proteinen  und 
Peptiden kann von einem erst  kürzlich entwickelten Antikörper erkannt 
werden.  Durch  die  Benützung  dieses  anti-oligomer  spezifischen 
Antikörpers  konnten  wir  nichtfibrilläre,  toxische  Oligomere  in  Drusen 
entdecken. Im Gegensatz dazu waren keine Oligomere in Kontrollaugen 
ohne  Drusen  zu  finden.  Dieses  Ergebnis  schlägt  vor,  daβ  amyloidale 
Oligomere  in  der  Enstehung  von  Drusen  involviert  sind  und  daβ  ein 
ähnlicher  Proteinmissfaltungsprozeβ  in  AMD  und  amyloidalen 
Erkrankungen stattfindet.
52
Acknowledgements
Mario Isas, PhD
My first acknowledgement goes to Mario Isas for his constant support in 
science and life.
Jeannie Chen, PhD and Ralf Langen, PhD
I would like to thank Jeannie and Ralf for their trust in giving me the great
opportunity to become a member of their laboratories and work on this 
exciting project.
Prof. Dr. Eckhard Wolf
I  would  like  to  thank  Eckhard  Wolf  for  making  this  (life)  experience 
possible.
and all the members of the Chen and Langen Lab
especially  Angela  Roca,  Christine  Jao,  Torsten  Fischer  and  Francis 
Concepcion
53
